Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Andrew McCreath
Cardio Pharma CorpCOM.TODON'T BUYApr 20, 2004
Had some interesting trial data. Shares have moved up quite nicely, but now priced with good news built-in. Fully valued.
$6.96
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
There were concerns on FDA approval, but he feels these are not major and the drug is good. Expect it will be taken over.
Peter HodsonOwned
biotechnologypharmaceutical
BUY
Have some excellent drugs. Data is coming out which they hope will be very good in the next 3/6 months.
Hugh McCauleyOwned
biotechnologypharmaceutical
BUY
Has something that is very competitive in arrhythmia. A good one to take a look at.
Michael SmedleyOwned
biotechnologypharmaceutical
